Chemistry and structural evaluation of different phospholipase A2 inhibitors in arachidonic acid pathway mediated inflammation and snake venom toxicity

Current Topics in Medicinal Chemistry

Volumn 7, Issue 8, 2007, Pages 787-800

  Narendra Sharath Chandra, J N ^a   Ponnappa, K C ^a   Sadashiva, C T ^a   Priya, B S ^a   Nanda, B L ^a   Verrabasappa Gowda, T ^a   Vishwanath, B S ^a   Rangappa, K S ^a  

^a UNIVERSITY OF MYSORE   (India)

Author keywords

Inflammation; Isoxazoline; Piperazine; PLA2 inhibitors; Snake venom toxicity

Indexed keywords

ACENAPHTHENE DERIVATIVE; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; ARISTOLOCHIC ACID; AZETIDINONE DERIVATIVE; DIAZEPINONE DERIVATIVE; HORSFIELDIA AMYGDALINE EXTRACT; INDOLE DERIVATIVE; INDOMETACIN; ISOENZYME; ISOXAZOLIDINE DERIVATIVE; ISOXAZOLINE DERIVATIVE; LY 311727; MANOALIDE; MANOALOGUE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE INHIBITOR; PHOSPHOLIPID DERIVATIVE; PIPERAZINE DERIVATIVE; PLANT EXTRACT; RETINAL; RETINOIC ACID; RETINOL; RF 143; SCALARADIAL; SNAKE VENOM; THIELOCIN A1BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 26567; YM 26734;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARACHIDONIC ACID METABOLISM; CATALYSIS; DRUG STRUCTURE; ELECTRON TRANSPORT; ENZYME INHIBITION; FRUIT; HORSFIELDIA AMYGDALINE; HUMAN; HYDROPHOBICITY; INFLAMMATION; MEDICINAL PLANT; NONHUMAN; PLEURISY; REVIEW; SNAKEBITE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ARACHIDONIC ACID; ENZYME INHIBITORS; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE; PHOSPHOLIPASES A; SNAKE VENOMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247585152     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780487678     Document Type: Review

References (81)

1. Iwanaga, S.; Suzuki, T. Enzymes in snake venom. In: Hand book of experimental pharmacology. (Lee and C.Y., Ed) Berlin Springer 1979 Vol. 52, 61.
2. Tu, A.T (Ed). Venoms: Chemistry and Molecular Biology. New York; John Wiley, 1977.
3. Chakraborti, S. Phospholipase A (2) isoforms: A perspective. Cell Signal, 2003, 15, 637.
4. Pruzanski, W.; Bogoch, E.; Stefanski, E.; Wloch, M.; Vadas, P. 1994 Enzymatic activity and distribution of phospholipase A2 in human cartilage. Life Sci. 1991, 48(25), 2457-62.
5. 2 enzymes: classification and characterization. Biochim. Biophys. Acta 2000, 1488, 1.
6. 2 purified from porcine pancreas and snake venoms. Toxicon 1993, (8), 949-56.
7. 2. Toxicon 1989, 27 6), 613-35.
8. 2 enzymes: Structure, function and mechanism, Wiley, Chichester, 1997, 245-268.
9. Kini, R. M.; Iwanaga, S, Structure-function relationships of phospholipase I: Prediction of presynaptic neurotoxicity. Toxicon 1986, 24, 527.
10. 2 from Bothrops neuwiedii venom. Arch. Biochem. Biophys. 1995, 318, 65.
11. 2. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 175-189.
12. 2 induces an inflammatory response in rabit joints. J. Immunol. 1991, 146(11), 3904-3910.
13. 2 purified from human synovial fluid and inhibition by aristolochic acid. Inflammation 1988, 12(6), 549-561.
14. Vadas, P.; Browning, J.; Edelson, J.; Pruzanski, W. Extracellular phospholipase A2 expression and inflammation: The relationship with associated disease states. J. Lipid Mediat. 1993, 8 1), 1-30.
15. 2 by retinoids and flavonoids. Mechanism of action. Inflammation 1988, 12, 549.
16. 2 induced pleural inflammation in rats. Int. J. Tissue React. 1989, 11, 129.
17. 2. Rev. Physiol. Biochem. Pharmacol. 1981 91, 91.
18. Yedgar, S.; Cohen, Y.; Shoseyov, D. Control of phospholipase A(2) activities for the treatment of inflammatory conditions. Biochim. Biophys. Acta 2006, 176(11), 1373-82.
19. Braguet, P.; Shen, T. Y.; Touqui, L.; Vargafting, B. Pharmacol. Rev. 1987, 39, 97.
20. Needleman, P.; Turk, J.; Wykle, R. L. J. Bio. Chem. 1986, 261, 9128.
21. Synder, F. Ann. Rep. Med. Chem. 1983, 17, 314.
22. Yedgar, S.; Lichtenberg, D.; Schnitzer E. Inhibition of phospholipase A(2) as a therapeutic target. Biochim. Biophys. Acta 2000, 1488(1-2), 182-7.
23. 2 and their pathophysiological significance in inflammatory diseases. Curr. Mol. Med. 2001, 1, 739.
24. 2 and diclofenac at 2.7 A resolution. Acta Crystallogr. D Biol. Crystallogr. 2006, 62 (Pt 4), 410-6.
25. 2) from the Indian cobra (Naja naja naja) venom. Biochem 1991, Int. 25, 1023.
26. 2 enzymes: Structure, Function and Mechanism. Ed. R. M. Kini, John Wiley and Sons. New York, 1997, 155-183.
27. 2 and a designed peptide Leu-Ala- Ile-Tyr-Ser (LAIYS). Acta Crystallogr. D Biol. Crystallogr. 2002, 58(Pt 10 Pt 2), 1813-9.
28. 2 according to sequence. Evolutionary and pharmacological implications. Eur. J. Biochem. 1983, 137, 545-551.
29. 2. J. Mol. Biol. 2003, 333(2), 367-76.
30. 2, affects its pharmacological activities. Toxicon 1993, 31, 1202.
31. Davidson, F. F.; Deniss, E. A.; Powell, M.; Glenny, J. R. J. Bio. Chem. 1987, 262, 1698.
32. Jameel, N. M.; Frey, B. M.; Frey, F. J.; Gowda, T. V.; Vishwanath, B. S. Inhibition of secretory phospholipase A(2) enzyme by bilirubin: A new role as endogenous anti- inflammatory molecule. Mol. Cell. Biochem. 2005, 276(1-2), 219-25.
33. 2 from Vipera russelli venom with aristolochic acid: A circular dichroism study. Taxicon 1987, 25(9), 939.
34. 2 by retinoids and flavonoids. Mechanism of action. Agents Actions 1988, 25(3-4), 394.
35. 2. Biochem. Pharmacol. 1986, 35, 449-453.
36. 2 enzymes. Biochem. J. 1996, 320, 93-99.
37. Jacobs, R. S.; Culver, P.; Langdon, R.; Obrien, T.; WNte, S. Some pharmacological observation on marine natural products. Tetrahedron 1985, 41, 981-984.
38. 2 inhibitor thielocin A/β and mechanism of action. J. Antibiotics 1992, 45, 1071-1078.
39. Miyake, A.; Yamamoto, H.; Takebayashi, Y.; Lmai, H.; Honda, K. The novel natural product
40. Horigone, K.; Hayakawa.; Inoue, K.; Nojima, S. J. Biochem. 1987 101, 53.
41. 2 inhibitors from ascomycetes. J. Antibiotics. 1991, 44, 1467-1470.
42. Vishwanath, B. S.; Fawazy, A.A. Ederma-inducing activity from human synovial fluid and inhibition by aristolochic acid. Inflammation 1988, 12, 6.
43. 2 enzymes from habu (Trimeresurus flavoviridis) venom and their interaction with the alkaloid aristolochic acid. Toxicon 1987, 25(5), 501-15.
44. 2 activity and arachidonate metabolism of human neutrophils. Biochim. Biophys. Acta 1989, 23, 1001(1), 1-8.
45. 2: Its effect on enzymatic and pathological activities. Toxicon 1987, 25(9), 929-37.
46. 2 from Vipera russelli venom with aristolochic acid: A circular dichroism study. Toxicon. 1987, 25(9), 939-46.
47. 2 from viper Russelli venom with aristacholic acid: A circular dichroism study. Toxicon 1987, 25, 939-946.
48. 2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from 1.7A° crystal structure. Biochemistry, 2002, 41 10914-10919.
49. Gluser, K. B.; Jacobs, R. S. Biochem. Pharm. 1986, 35 449.
50. 2 by reaenoids and flavanoids. Mechanism of action. Agents and actions, 1988, 25, 314, 394-400.
51. Bosen, P. P. M. et al, Biochim. Biophys, 1972, 364-367.
52. Verheij, H. M.; Slotboom, A. J.; de Hass, G. H. Rev. Physio. Biochem Pharmacol. 1981, 91, 91-93.
53. Yuen, W.; Berman, R. J.; Gelb, M. H. J. Am. Chem. Soc. 1987 109, 8071.
54. Yuan, W.; Gelb, M. H. J. Am. Chem. Soc. 1988, 110, 2665.
55. Lister, M. D.; Hancock, A. J. J. Lipid. Res. 1988, 29 1297.
56. 2. Nat. Stru. Bio. 1995, 2, 458-465.
57. 2 with anti-inflammatory activity. Lett. Drug Design Discov. 2005, 2, 307-310.
58. 2, Nat. Struct. Biol. 1995, 2, 458465.
59. 2 inhibition: Synthesis and structure activity relationship in 1-arylsulfamido-2-alkylpiperazines. Eur. J Med. Chem. 2001, 36, 809-828.
60. 2 with anti-inflammatory activity. Inter. J. Mol. Med. 2005, 16 895-904.
61. 2 hihibitors. Bioorg. Med. Chem. Lett. 2004, 14(14), 3679-81.
62. Jackermann, E. J.; Conde-Frieboes, K.; Dennis, E. A. Inhibition of macrophage Ca(2+)-independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J. Biol. Chem. 1995, 270 (1), 445-50.
63. 2. J. Biol Chem. 1991, 266, 7227.
64. 2 by manolide and manoalogue. Stoichiometri of incorporation. J. Chem. 1991, 266, 16512.
65. Desouza, P. L. et al. Enhancement of paclitaxel activity against barmone refractory prostate cancer cells in invitro, and invivo by Quinacrina. Br. J. Cancer 1997, 75, 1593.
66. 2 production in in vivo of the macrophage-like P388D1 cells. Effects of manolide, 7, 7-dimethyl-5,8-eicosodienoic acid and p-bromophencyl bromide. J. Biol. Chem. 1989, 264, 8520.
67. 2 with anti-inflammatory activity. Curr. Ttopics in Med. Chem (communicated).
68. 2 activity in hyperbilirubinemia. Hepatogastroenterology 2000, 47 35), 1223-6.
69. 2 with Membranes, Biochemistry 1993, 32, 13902-13908.
70. 2 Inhibition for the Synthesis of Prostaglandins by the Plant Alkaloid Aristolochic Acid from a 1.7 Å Crystal Structure. Biochemistry 2002, 41 (36), 10914-10919.
71. 2 prevents arachidonic acid incorporation and phopholipid remodeling in p38 macrophages. PNAS 1995, 92, 8527-8531.
72. 2 inbibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation. J. Pharmacol. Exp. Ther. 1994, 268, 709-717.
73. 2 and specific inhibitors of 5-lipoxygenase, Agents Actions 1991 34, 89.
74. Hirohata. et al Rapid induction of neutrophil apoptosis by sulfasalazine: Implications of reactive oxygen species in the apoptotic process: Akahoshi, T. et al.; J. Leukoc. Biol. 1997, 62 817.
75. Jacobson, P.B. et al. Inactivation of human synovial fluid phospholipase A2 by the marine natural product, manoalide. Biochem. Pharmacol. 1990, 39, 1557.
76. 2 (sPLA2) by sulfasalazine, a novel mechanism of anti- inflammatory activity, Biochem. Pharmacol. 1997, 53, 1901.
77. Albizati, K. F. et al. Luffariellolide, an anti-inflammatory sesterpene from the marine sponge Luffariella spp. Experientia, 1987, 43, 949-950.
78. 2 inhibitors in development. Friebe W. G. Expert Opin. Investig. Drugs 1997, 6(3), 279-98.
79. 2 by electrostatic fields and dipole potential of glycosphingolipids in monolayers. The J. Lipid Res. 1999, 40, 930-939.
80. 2 inhibitors. Inter. J. Mol. Med. (communicated).
81. Narendra Sharath Chandra, J. N.; Sadashiva, C. T. Kavitha, C. V.; Rangappa, K. S. Synthesis and in vitro antimicrobial studies of medicinally important novel N-alkyl and N-sulfonyl derivatives of 1-[bis(4-fluorophenyl)-methyl]piperazine. Bioorg. Med. Chem. 2006, 14(19), 6621-7.